Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052).
Level II
Where this comes from
- Record sourced from PubMed, PMID 23908493.
- Also identified by DOI 10.1093/infdis/jit390 and PMC identifier 3805242.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The HIV Prevention Trials Network 052 study enrolled serodiscordant couples. Index participants infected with human immunodeficiency virus reported no prior antiretroviral (ARV) treatment at enrollment. ARV drug testing was performed retrospectively using enrollment samples from a subset of index participants. ARV drugs were detected in 45 of 96 participants (46.9%) with an undetectable viral load, 2 of 48 (4.2%) with a low viral load, and 1 of 65 (1.5%) with a high viral load (P < .0001); they were also detected in follow-up samples from participants who were not receiving study-administered treatment. ARV drug testing may be useful in addition to self-report of ARV drug use in some clinical trial settings.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- HIV-1